ALAS PROPIAS: BMGIM for Professionals Working in Intimate Partner Machista Violence Services
Condition(s) studied
Investigational drug(s) / intervention(s)
ALAS PROPIAS - Individual Music Therapy BMGIM: The ALAS PROPIAS intervention consists of 10 individual music therapy sessions using the Bonny Method of Guided Imagery and Music (BMGIM), aimed at professionals working in services supporting women experiencing machista violence in intimate partner relationship. The intervention focuses on exploring imagery, emotions, and sensations through guided music listening, followed by a process of integration and reflection. The program aims to evaluate changes in burnout, compassion fatigue, vicarious trauma, secondary traumatic stress, anxiety, positive and negative affect, emotional regulation, psychological well-being, and professional well-being among participants.
Study summary
This study evaluates the impact of a 10-session individual music therapy intervention using the Bonny Method of Guided Imagery and Music (BMGIM) on the well-being and psychological health of professionals working in services supporting women experiencing intimate partner machista violence.
The study uses a controlled, non-randomized quasi-experimental design, with an experimental group and a wait-list control group. Changes in burnout, compassion fatigue, vicarious trauma, secondary traumatic stress, anxiety, positive and negative affect, emotional regulation, and professional well-being are assessed.
Eligibility
Primary outcome measure(s)
- Change in Burnout — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
Burnout will be assessed using the Spanish adaptation of the Maslach Burnout Inventory (MBI) (Maslach \& Jackson, 1981; Seisdedos, 1997). Scores at the final assessment will be compared with baseline scores to evaluate changes in burnout among participants in the experimental and wait-list control groups. - Change in Positive and Negative Affect — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
Positive and negative affect will be assessed using the Spanish adaptation of the Positive and Negative Affect Schedule (PANAS) (Sandín et al., 1999). Scores at the final assessment will be compared with baseline scores to evaluate changes in positive and negative affect in the experimental and wait-list control groups. - Change in Psychological Well-Being — Psychological well-being will be assessed using the Spanish adaptation of Ryff's Psychological Well-Being Scales (Díaz et al., 2006). Scores at the final assessment will be compared with baseline scores to evaluate changes in psychological well-being in
Psychological well-being will be assessed using the Spanish adaptation of Ryff's Psychological Well-Being Scales (Díaz et al., 2006). Scores at the final assessment will be compared with baseline scores to evaluate changes in psychological well-being in the experimental and wait-list control groups. - Change in Professional Quality of Life — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
Professional quality of life will be assessed using the Spanish adaptation of the Professional Quality of Life Scale, version 5 (ProQOL-5) (Galiana et al., 2020). Scores at the final assessment will be compared with baseline scores to evaluate changes in professional quality of life in the experimental and wait-list control groups. - Change in Secondary Traumatic Stress — Baseline (T0), Immediate Post-intervention (T1), 3-month Follow-up (T2)
Secondary traumatic stress will be assessed using the Secondary Traumatic Stress Scale (STSS) (Guerra \& Saiz, 2007). Scores at the final assessment will be compared with baseline scores to evaluate changes in secondary traumatic stress in the experimental and wait-list control groups.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Universidad Miguel Hernández de Elche | Elche | Alicante |
More Universidad Miguel Hernandez de Elche trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07925736 on ClinicalTrials.gov ↗ ← All trials in Spain